Summary
Becton, Dickinson and Company (BDX) reported robust revenue growth of 18.3% in fiscal year 2021, reaching $20.25 billion, driven by a significant recovery in medical procedures and strong demand across its Medical, Life Sciences, and Interventional segments. The Life Sciences segment, in particular, saw a substantial boost from COVID-19 diagnostic testing solutions. Despite global economic uncertainties and supply chain challenges exacerbated by the pandemic, BD demonstrated strong operating performance and cash flow generation, with operating income reaching $2.8 billion. The company continues to invest in R&D and strategic initiatives aimed at innovation and efficiency, as outlined in its BD 2025 strategy. BD also reaffirmed its commitment to shareholder returns through dividends and share repurchases. Looking ahead, BD announced its intention to spin off its Diabetes Care business into a separate publicly traded company, a strategic move aimed at allowing both entities to focus on their respective growth strategies and capital allocation. The company also navigated various risk factors, including the ongoing impact of the COVID-19 pandemic, supply chain disruptions, and ongoing regulatory considerations, while maintaining effective internal controls. The company's financial position remains strong, supported by healthy cash flows and access to credit facilities.
Financial Highlights
56 data points| Revenue | $19.13B |
| Cost of Revenue | $10.50B |
| Gross Profit | $8.63B |
| R&D Expenses | $1.28B |
| SG&A Expenses | $4.72B |
| Operating Expenses | $16.88B |
| Operating Income | $2.25B |
| Interest Expense | $469.00M |
| Net Income | $2.09B |
| EPS (Basic) | $6.92 |
| EPS (Diluted) | $6.85 |
| Shares Outstanding (Basic) | 289.29M |
| Shares Outstanding (Diluted) | 292.09M |
Key Highlights
- 1Total revenue for fiscal year 2021 reached $20.25 billion, an increase of 18.3% compared to the prior year, driven by volume increases, favorable foreign currency, and price adjustments.
- 2The Life Sciences segment experienced significant growth, up 39.7%, largely fueled by COVID-19 diagnostic testing on the BD Veritor™ Plus and BD Max™ Systems, alongside improved demand for specimen management and automated blood cultures.
- 3The Medical segment's revenue grew by 9.2%, with strong performance in Medication Delivery Solutions and Pharmaceutical Systems, supported by increased demand for core products and conversion to pre-filled devices.
- 4The Interventional segment saw a 12.7% revenue increase, benefiting from higher hospital utilization and new product offerings in its Surgery and Peripheral Intervention units.
- 5Operating income improved significantly to $2.8 billion from $1.48 billion in the prior year, reflecting better gross profit margins across segments and improved operating expense management.
- 6BD generated $4.65 billion in cash flow from operating activities, demonstrating strong cash generation to support investments, dividends, and share repurchases.
- 7The company announced its intention to spin off its Diabetes Care business, expected to be completed in the first half of calendar year 2022, to create two focused, publicly traded entities.